Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02427581 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Drugs not available

Conditions

Triple Negative Breast Cancer
Triple Negative Breast Neoplasms
Triple-Negative Breast Cancer

Interventions

BIOLOGICAL: Personalized synthetic long peptide vaccine (Poly ICLC)
DRUG: Poly ICLC

Sponsor

Washington University School of Medicine

Collaborators

[object Object]